Study of HyQvia for Adults with CIDP in Routine Care
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well HyQvia works for adults with CIDP in everyday medical practice. It includes people who are already using HyQvia or are switching to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) by a doctor.
- Your CIDP symptoms have been stable for at least 12 weeks.
- You are either planning to switch to HyQvia within 6 weeks, or you have already started HyQvia in the last 6 weeks.
- You are willing to follow study procedures and attend scheduled assessments.
- You are not pregnant or breastfeeding, and you have no known allergy to HyQvia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
This trial tests a new antibody drug called obinutuzumab β for people with a long-term nerve condition called CIDP. It aims to see if the drug can help reduce symptoms and improve daily function.
This study looks at how HyQvia (an immune-boosting medicine given under the skin) is used in real life for adults with multiple myeloma and secondary immune problems. It may help doctors understand what works best and how patients do when HyQvia is used routinely.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
This study tests Hizentra® as an alternative to IV immunoglobulin (IVIg) for adults with CIDP, a condition where the immune system damages the nerves. You may be able to switch to Hizentra if your current IVIg treatment is keeping your CIDP stable and you can switch safely.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.